Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes | Latest News RSS feed

Brieffda Approves Sglt2 Inhibitor Steglatro And Fixeddose Combination Steglujan For Adults With Type 2 Diabetes - Latest News


BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

* MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ORAL SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, AND FIXED-DOSE COMBINATION STEGLUJAN TABLETS * MERCK & CO INC - IN ADDITION TO STEGLATRO & ... read more

New SGLT2 Competitor Steglatro Approved for Type 2 Diabetes

The sodium-glucose co-transporter 2 (SGLT2) class of medications to treat type 2 diabetes just got another competitor as the FDA approved ertugliflozin ... control. The fixed-dose of Steglatro and ... read more

Merck/Pfizer undercut rivals with newly approved diabetes drug

Merck and Pfizer are to take on the crowded SGLT2 inhibitor market with a keenly-priced new contender. The FDA approved Steglatro ... control in adults with type 2 diabetes. Meanwhile Steglujan ... read more

Looking for another news?


FDA OKs SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes

Officials with the FDA have approved ertugliflozin (Steglatro, Merck and Pfizer) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes ... of 2 fixed-dose ... read more


New Diabetes Treatments and Clinical Practice Aids

This approval permits Merck and Pfizer to market Steglatro as single therapy as well as Steglujan, a fixed dose combination with sitagliptin (Januvia), a DDP-4 inhibitor ... improve glycemic control ... read more

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use ... read more

Pfizer Ltd (PFIZ.BO)

Dec 22 (Reuters) - Merck & Co Inc ::FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES.MERCK ... read more

BRIEF-FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes

Dec 22 (Reuters) - Merck & Co Inc: * FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES * ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us